---
title: "HIMS Bulls Should Heed This Historic Chart Signal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298955828.md"
description: "Hims & Hers Health (HIMS) stock faces a historically bearish signal, with its 50-day put/call ratio exceeding 98% of past year readings. Historical data indicates a 100% probability of decline and an average 15% loss one month after such signals. Despite current analyst consensus favoring buys and a price target of $31.53, options market metrics suggest low volatility expectations and potential for further downside."
datetime: "2026-09-14T19:26:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298955828.md)
  - [en](https://longbridge.com/en/news/298955828.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298955828.md)
generator: "portal-rs"
---

# HIMS Bulls Should Heed This Historic Chart Signal

Drugmaker **Hims & Hers Health Inc (NYSE:HIMS)** stock is moving 6.6% higher to trade at $29.34 this afternoon. Despite its two-day pop, the shares have fumbled longer term, struggling to recover from a drawdown from its early July highs. Now off 3% in 2026, another pullback could be looming, with the 260-day moving average overhead and a historically bearish signal now flashing.

HIMS sports a 50-day call/put volume ratio of 4.53 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 98% of readings from the past year. There have been three instances in the last three years that the equity's 50-day buy-to-open put/call ratio crossed over 1.0 and moved into the 90th percentile. 

Per Schaeffer's Senior Quantitative Analyst Rocky White, **the drugmaker** was lower one month later 100% of the time after these signals, averaging a 15% loss. From its current perch, a move of similar magnitude would place the stock just above $25. 

Echoing this, Hims & Hers Health stock sports a Schaeffer's put/call open interest ratio (SOIR) of 0.61. This ratio ranks higher than just 29% of readings from the past year, suggesting short-term bears have plenty of room to move in.

There is ample opportunity for downgrade and price-target cuts, too. Heading into today, 36 of the 44 covering brokerages sport a "buy" or "strong buy" recommendation. Plus, the average 12 months price target of $31.53 comes in at a 7.5% premium to current levels.

Options are looking affordable as well, per the stock's Schaeffer's Volatility Index (SVI) of 39%, which stands higher than just 9% of all other readings from the past year. In other words, near-term option traders are pricing in relatively low volatility expectations at the moment.

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md)
- [CBOE.US](https://longbridge.com/en/quote/CBOE.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Hims & Hers Asks Judge to Toss FTC Lawsuit over Subscription Payments and User Data](https://longbridge.com/en/news/302774597.md)
- [Hims & Hers Health Expands Testosterone Care With Injectable And Oral TRT](https://longbridge.com/en/news/302564954.md)
- [Hims & Hers Health launches online weight management service for men in Germany](https://longbridge.com/en/news/302427301.md)
- [Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit](https://longbridge.com/en/news/302914090.md)
- [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**